➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
Johnson and Johnson
Dow
Medtronic

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SYMBICORT

» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Symbicort

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00812682 Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler Completed AstraZeneca N/A 2006-09-01 This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Symbicort

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00159263 Effect of Symbicort on GR Localisation in Asthma Completed AstraZeneca N/A 2004-11-01 To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction.
NCT00159263 Effect of Symbicort on GR Localisation in Asthma Completed Imperial College London N/A 2004-11-01 To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction.
NCT00206154 A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients Completed AstraZeneca Phase 3 2005-04-01 The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Symbicort

Condition Name

Condition Name for Symbicort
Intervention Trials
Asthma 80
Chronic Obstructive Pulmonary Disease 14
Chronic Obstructive Pulmonary Disease (COPD) 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Symbicort
Intervention Trials
Asthma 65
Lung Diseases 32
Pulmonary Disease, Chronic Obstructive 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Symbicort

Trials by Country

Trials by Country for Symbicort
Location Trials
United States 473
Japan 88
China 86
Germany 51
Canada 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Symbicort
Location Trials
California 20
Pennsylvania 20
Texas 20
Florida 18
South Carolina 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Symbicort

Clinical Trial Phase

Clinical Trial Phase for Symbicort
Clinical Trial Phase Trials
Phase 4 35
Phase 3 64
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Symbicort
Clinical Trial Phase Trials
Completed 101
Recruiting 14
Terminated 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Symbicort

Sponsor Name

Sponsor Name for Symbicort
Sponsor Trials
AstraZeneca 80
Orion Corporation, Orion Pharma 9
GlaxoSmithKline 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Symbicort
Sponsor Trials
Industry 126
Other 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Dow
Merck
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.